{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:11:13Z","timestamp":1779127873389,"version":"3.51.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018557","name":"Nantong Science and Technology Project","doi-asserted-by":"crossref","award":["MSZ20180"],"award-info":[{"award-number":["MSZ20180"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study used microscope-integrated optical coherence tomography (MIOCT) to identify patients with proliferative diabetic retinopathy with concurrent diabetic macular edema (DME) during vitrectomy and compared the efficacy of immediate versus delayed anti-VEGF treatment, as well as ranibizumab versus conbercept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A prospective randomized controlled trial was conducted on patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy (PPV). Patients with preoperatively unconfirmed DME were evaluated intraoperatively using MIOCT. Those with MIOCT-confirmed DME were randomly assigned to three groups: Group A received intravitreal ranibizumab during PPV with additional injections at 1 and 2 months postoperatively. Group B received intravitreal conbercept during PPV with additional injections at 1 and 2 months postoperatively. Group C received ranibizumab at 1, 2, and 3 months postoperatively. All groups followed a 3+ PRN protocol. Best-corrected visual acuity and central macular thickness were measured at 1 day; 1 week; 1, 3, and 6 months post-PPV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 115 eyes from 115 patients with proliferative diabetic retinopathy (one eye per patient) with MIOCT-confirmed concurrent DME during PPV were enrolled and randomly assigned to treatment groups. Six eyes were lost to follow-up, and 109 eyes (94.8%) completed the entire 6-month study. Groups A and B showed significant best-corrected visual acuity and central macular thickness improvements compared with Group C throughout the follow-up period, with Group B demonstrating superior early and sustained efficacy. Immediate anti-VEGF treatment during PPV, particularly with conbercept, was associated with reduced complications and accelerated recovery of visual function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In patients with proliferative diabetic retinopathy with MIOCT-identified DME during vitrectomy, immediate anti-VEGF treatment provides superior best-corrected visual acuity and central macular thickness improvements compared with delayed treatment, with conbercept demonstrating better efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004801","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:00:24Z","timestamp":1771020024000},"page":"1046-1056","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY"],"prefix":"10.1097","volume":"46","author":[{"given":"Jian","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Rong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260518","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3109\/02713683.2013.820327","article-title":"Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling","volume":"38","author":"Yamada","year":"2013","journal-title":"Curr Eye Res"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"R3-20260518","first-page":"249","article-title":"New progress in the treatment of diabetes macular edema after vitrectomy","volume":"43","author":"Li","year":"2023","journal-title":"New Prog Ophthalmol"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ophtha.2017.12.037","article-title":"The DISCOVER study 3-Year results: feasibility and usefulness of microscope-integrated intraoperative OCT during ophthalmic surgery","volume":"125","author":"Ehlers","year":"2018","journal-title":"Ophthalmology"},{"key":"R5-20260518","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","article-title":"Visual acuity as an outcome measure in clinical trials of retinal diseases","volume":"114","author":"Beck","year":"2007","journal-title":"Ophthalmology"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"R7-20260518","first-page":"483","article-title":"Efficacy of 25G pars plana vitrectomy with Conbercept intravitreal injection at the end of surgery for early proliferative diabetic retinopathy with vitreous hemorrhage","volume":"23","author":"Zhang","year":"2023","journal-title":"Int Eye Sci"},{"key":"R8-20260518","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/IAE.0b013e3182753b12","article-title":"Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy","volume":"33","author":"Christoforidis","year":"2013","journal-title":"Retina (Philadelphia, Pa)"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"8882539","DOI":"10.1155\/2021\/8882539","article-title":"Comparison of intravitreal dexamethasone implant and ranibizumab in vitrectomized eyes with diabetic macular edema","volume":"2021","author":"Wang","year":"2021","journal-title":"J Ophthalmol"},{"key":"R11-20260518","first-page":"105","article-title":"Intravitreal injection of conbercept after operation in the treatment of proliferatived diabetic retinophathy complicated with vitreous hemorrhage","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin J Ocul Dis"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1007\/s40123-023-00803-z","article-title":"Combined use of Anti-VEGF drugs before and during pars plana vitrectomy for severe proliferative diabetic retinopathy","volume":"12","author":"Sun","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R13-20260518","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ophtha.2004.03.035","article-title":"Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy","volume":"111","author":"Itakura","year":"2004","journal-title":"Ophthalmology"},{"key":"R14-20260518","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1097\/IAE.0000000000001490","article-title":"Persistent overproduction of intraocular vascular endothelial growth factor as a cause of late vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy","volume":"37","author":"Wakabayashi","year":"2017","journal-title":"Retina (Philadelphia, Pa)"},{"key":"R15-20260518","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1167\/iovs.12-10367","article-title":"Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy","volume":"53","author":"Wakabayashi","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjo.2005.087403","article-title":"Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis","volume":"90","author":"Patel","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R17-20260518","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s13063-023-07735-w","article-title":"Microinvasive pars plana vitrectomy combined with internal limiting membrane peeling versus anti-VEGF intravitreal injection for treatment-na\u00efve diabetic macular edema (VVV-DME study): study protocol for a randomized controlled trial","volume":"24","author":"Guo","year":"2023","journal-title":"Trials"},{"key":"R19-20260518","first-page":"255","article-title":"The complication after intravitreal Anti-VEGF medications","volume":"32","author":"Tu","year":"2008","journal-title":"Int Overview Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:00:34Z","timestamp":1779127234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004801","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}